Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study

Charles V. Pollack, Jeffrey I. Weitz, Robert Dubiel et al.|Journal of Medical Economics|2016

Cited by 11